COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
作者信息
Capone Fioravante, Ferraro Elisabetta, Motolese Francesco, Di Lazzaro Vincenzo
机构信息
Neurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Institute of Neurology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.
San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
出版信息
J Neurol. 2021 Sep;268(9):3132-3134. doi: 10.1007/s00415-021-10446-4. Epub 2021 Feb 20.
Abstract
摘要
相似文献
1
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
J Neurol. 2021 Sep;268(9):3132-3134. doi: 10.1007/s00415-021-10446-4. Epub 2021 Feb 20.
2
COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
J Neurol. 2021 Jun;268(6):2023-2025. doi: 10.1007/s00415-020-10015-1. Epub 2020 Jun 25.
3
Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
J Neurol. 2021 Mar;268(3):941-949. doi: 10.1007/s00415-020-10226-6. Epub 2020 Sep 24.
4
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.
5
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
6
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
J Med Econ. 2015;18(11):874-85. doi: 10.3111/13696998.2015.1056794. Epub 2015 Jul 1.
7
Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Drug Des Devel Ther. 2017 Jul 28;11:2193-2207. doi: 10.2147/DDDT.S137572. eCollection 2017.
8
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Curr Med Res Opin. 2017 Feb;33(2):175-183. doi: 10.1080/03007995.2016.1248380. Epub 2016 Nov 10.
9
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):73-77. doi: 10.17116/jnevro202212207273.
10
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
BMC Res Notes. 2016 Sep 7;9(1):434. doi: 10.1186/s13104-016-2243-8.
引用本文的文献
1
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.
JAMA Netw Open. 2024 Apr 1;7(4):e246345. doi: 10.1001/jamanetworkopen.2024.6345.
2
New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate.
Pharmaceutics. 2022 Dec 6;14(12):2732. doi: 10.3390/pharmaceutics14122732.
3
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
J Neurol. 2022 Sep;269(9):4581-4603. doi: 10.1007/s00415-022-11237-1. Epub 2022 Jul 5.
4
COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study.
Neurol Ther. 2022 Sep;11(3):1135-1146. doi: 10.1007/s40120-022-00359-3. Epub 2022 May 12.
5
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.
CNS Drugs. 2021 Nov;35(11):1173-1188. doi: 10.1007/s40263-021-00863-4. Epub 2021 Oct 16.
6
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
7
The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.
Mol Neurobiol. 2021 Aug;58(8):4178-4187. doi: 10.1007/s12035-021-02438-2. Epub 2021 Jun 1.
8
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
本文引用的文献
1
SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.
Nat Commun. 2020 Oct 2;11(1):4938. doi: 10.1038/s41467-020-18764-3.
2
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.
J Neuroimmunol. 2020 Jul 15;346:577323. doi: 10.1016/j.jneuroim.2020.577323.
3
COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
J Neurol. 2021 Jun;268(6):2023-2025. doi: 10.1007/s00415-020-10015-1. Epub 2020 Jun 25.
4
COVID-19 in teriflunomide-treated patients with multiple sclerosis.
J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3.
5
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
J Neurol. 2020 Aug;267(8):2362-2371. doi: 10.1007/s00415-020-09848-7. Epub 2020 Apr 29.
6
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
7
IL-17 CD8 T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis.
Nat Commun. 2019 Dec 16;10(1):5722. doi: 10.1038/s41467-019-13731-z.
8
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.
Zotero 插件